HOME >> MEDICINE >> NEWS
Clinical trial of Etanercept for Wegener's disease shows no benefit

A Johns Hopkins-led study designed to evaluate the ability of etanercept to maintain disease remissions in a serious autoimmune disorder has failed to show any benefit. Etanercept, also called Enbrel, is a common treatment for rheumatoid arthritis and other types of joint inflammation.

"We had hoped that this approach to the treatment of Wegener's granulomatosis would be useful in preventing disease relapses," says John H. Stone, M.D., associate professor of medicine, director of the Johns Hopkins Vasculitis Center, and lead investigator of the study published in the Jan. 27, 2005, issue of the New England Journal of Medicine.

"The study results, however, demonstrate unequivocally that etanercept was not effective for this purpose. Because of the disease's propensity to flare following remission and the high risk of treatment complications associated with conventional therapies for Wegener's, we must continue to look for safe, effective ways of achieving and maintaining disease remissions," said Stone.

Wegener's granulomatosis is an uncommon disorder in which the body's immune system attacks its own blood vessels, damaging vital organs by limiting the flow of blood to lungs, kidneys, upper airways and other organs. The disease can affect people of any age and occurs in men and women with equal frequency.

Although current medications used to treat Wegener's halt the disease temporarily in most patients, 60 to 80 percent of patients eventually suffer from disease flares. The need to treat many patients repeatedly with medications such as glucocorticoids (prednisone), cyclophosphamide, and methotrexate leads to mounting morbidity from treatments. At the same time, each disease flare has the potential to cause irreversible damage. Wegener's granulomatosis frequently leads to kidney failure, hearing loss, damage to the respiratory tract, peripheral nerve injury, and other complications, according to Stone.

Etanercept, the f
'"/>

Contact: Trent Stockton
tstockt1@jhmi.edu
410-955-8665
Johns Hopkins Medical Institutions
26-Jan-2005


Page: 1 2 3

Related medicine news :

1. Clinical breast examination offers modest benefit to breast cancer screening program
2. Clinical trial participants fare no better, no worse than other patients
3. Clinical trial shows drug may offer a new option to prevent rejection of transplanted kidneys
4. National Academies news: Clinical research involving children
5. Clinical research key in advance to prospective health care
6. Clinical trial of new TB vaccine begins
7. Clinical trial of Alzheimers disease drug shows clear reductions in AD development
8. Clinical factors useful to identify heart failure patients with high risk of death
9. Panel: Clinical use of embryonic stem cells jeopardized by Bushs policy on federal funding
10. $7 million grant continues Asthma Clinical Research Network efforts
11. Clinical study of Penn State Hershey technology begins in South Africa

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/14/2019)... HUNTINGTON STATION, N.Y. (PRWEB) , ... June 14, ... ... announces an additional Pennsylvania Tempur-Pedic® Mattress & Pink Bag Event® scheduled for Saturday, ... to support additional women, men and children directly impacted by breast cancer. This ...
(Date:6/13/2019)... , ... June 13, 2019 , ... Endometriosis is a painful, inflammatory disease that occurs ... , Painful periods , Heavy bleeding , Irregular menstruation ... , Women’s Excellence uses the latest and newest treatment protocols in dealing with ...
(Date:6/13/2019)... ... June 13, 2019 , ... Charm Sciences, Inc. is ... been accepted by the 2019 National Conference of Interstate Milk Shipments for screening ... The Charm BL30SEC test was validated by third party laboratories working in collaboration ...
(Date:6/13/2019)... ... ... Hard money lenders like Monroe Funding Corporation are able to respond and approve ... If the documentation and collateral are immediately available, it’s possible to receive approval and ... with a traditional lender, which allows loans to be customized and adjusted based on ...
(Date:6/13/2019)... ... June 13, 2019 , ... Kno2 ®, ... announced that Jon Elwell, the company’s CEO, has been confirmed by the membership ... a non-profit health care industry alliance created to support secure, identity-proofed electronic exchanges ...
Breaking Medicine News(10 mins):
(Date:6/14/2019)... ... June 14, 2019 , ... ... forecasting and analytics platform that helps Life Sciences Manufacturers accurately project their ... Life Sciences business leaders: accurate, automated forecasting of rebates and discounts and ...
(Date:6/13/2019)... LOUISVILLE, Ky. (PRWEB) , ... June 13, 2019 , ... ... 12 months for a long-term client in the healthcare space. The $5.8M in savings ... total realized bottom line improvement to $23.4M. , With an acquisition in Q4 2019, ...
(Date:6/13/2019)... , ... June 13, 2019 , ... The American Psychiatric ... director to succeed current executive director Nicholas Croce Jr., MS. The search will be ... Board of Directors, past APNA Presidents, and Council and Chapter leaders. , The job ...
Breaking Medicine Technology:
Cached News: